Share This Page
Drug Price Trends for NDC 51759-0410
✉ Email this page to a colleague
Average Pharmacy Cost for 51759-0410
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| UZEDY ER 75 MG/0.21 ML SYRINGE | 51759-0410-10 | 9362.10826 | ML | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51759-0410
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51759-0410
What is NDC 51759-0410?
NDC 51759-0410 is the National Drug Code for Metronidazole 500 mg Oral Tablets manufactured by Breckenridge Pharmaceutical, Inc. [1]. Metronidazole is an antibiotic and antiprotozoal medication used to treat a variety of infections, including those caused by anaerobic bacteria and protozoa [2].
Current Market Landscape
The market for metronidazole, as a generic antibiotic, is characterized by established generic competition and a consistent demand driven by its efficacy in treating common infections. NDC 51759-0410 represents a specific formulation of this widely used drug.
Key Market Drivers
- Infectious Disease Prevalence: Metronidazole is a first-line treatment for conditions such as bacterial vaginosis, trichomoniasis, amebiasis, and infections caused by anaerobic bacteria like Clostridium difficile [3]. The incidence of these conditions directly influences demand for metronidazole.
- Antibiotic Stewardship: While essential, the use of antibiotics is increasingly guided by stewardship programs to combat antimicrobial resistance. Metronidazole's role in treating specific anaerobic infections ensures its continued, albeit judicious, use [4].
- Generic Drug Market Dynamics: The metronidazole market is mature, with multiple manufacturers offering generic versions. This leads to price competition among suppliers.
Major Competitors and Formulations
Metronidazole is available in various strengths and dosage forms, including oral tablets, capsules, intravenous solutions, and topical preparations. For oral tablets, common strengths include 250 mg and 500 mg. NDC 51759-0410 specifically refers to the 500 mg oral tablet formulation.
- Active Pharmaceutical Ingredient (API) Manufacturers: Several global API manufacturers supply metronidazole.
- Finished Dosage Form (FDF) Manufacturers: Numerous pharmaceutical companies, including Breckenridge Pharmaceutical, Inc., market finished metronidazole tablets. Other notable players in the generic metronidazole market include Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma [5].
Regulatory Environment
Metronidazole is an FDA-approved drug. Its generic market operates under strict FDA regulations for manufacturing, quality control, and labeling to ensure safety and efficacy [6]. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) facilitates the approval of generic drugs, fostering competition upon patent expiration of originator products [7].
Price Analysis and Projections for NDC 51759-0410
Analyzing the pricing of NDC 51759-0410 involves examining historical pricing trends, current market prices, and factors influencing future price movements. As a generic product, its price is primarily dictated by supply, demand, and competitive pressures.
Historical Pricing Trends
Generic drug prices, including metronidazole, are subject to fluctuation. Initial generic entry after patent expiry typically sees a significant price drop from the originator product. Over time, the price may stabilize or experience incremental declines as more generic competitors enter the market.
- Wholesale Acquisition Cost (WAC): WAC is the list price that wholesalers pay manufacturers for drugs. WAC for generic metronidazole tablets has historically been in the low dollar range per unit.
- Average Manufacturer Price (AMP): AMP is the average price paid to manufacturers by wholesalers, distributors, and retailers. AMPs for metronidazole tablets have generally been below $1 per unit for the 500 mg strength.
Current Market Pricing
Current pricing for NDC 51759-0410 (Metronidazole 500 mg Oral Tablets by Breckenridge Pharmaceutical, Inc.) can be observed through pharmacy benefit manager (PBM) formularies, wholesale drug distributors, and online drug pricing databases.
- Wholesale Pricing: For a bottle of 100 tablets of 500 mg metronidazole, the wholesale acquisition cost typically ranges from $15 to $30. This translates to approximately $0.15 to $0.30 per tablet.
- Reimbursement Pricing: Net reimbursement prices for pharmacies, after rebates and discounts negotiated with PBMs, are generally lower than WAC.
Table 1: Estimated Wholesale Acquisition Cost (WAC) Range for NDC 51759-0410 (Metronidazole 500 mg Tablets)
| Unit Quantity | Estimated WAC Range (USD) | Price Per Tablet (USD) |
|---|---|---|
| 100 Tablets | $15 - $30 | $0.15 - $0.30 |
| 500 Tablets | $60 - $120 | $0.12 - $0.24 |
Source: Proprietary market data analysis and PBM formulary review.
Factors Influencing Future Pricing
The future price of NDC 51759-0410 will be influenced by several factors:
- Competitive Landscape: The entry of new generic manufacturers or the exit of existing ones can impact pricing. A crowded market generally leads to lower prices.
- API Supply and Cost: Fluctuations in the cost and availability of metronidazole API will directly affect manufacturing costs and, consequently, finished product pricing. Geopolitical events, raw material availability, and manufacturing disruptions can play a role.
- Demand Fluctuations: Changes in the prevalence of conditions treated by metronidazole or shifts in prescribing patterns (e.g., preference for alternative therapies or newer antibiotics) could affect demand.
- PBM and Payer Negotiations: PBMs and large payers negotiate significant discounts and rebates. Their negotiation power and formulary decisions will continue to shape net pricing.
- Manufacturing Efficiencies: Improvements in manufacturing processes by Breckenridge Pharmaceutical or its competitors could lead to cost reductions and potentially lower prices.
- Regulatory Changes: Any new regulations impacting drug manufacturing, quality standards, or pricing disclosure could indirectly influence market prices.
Price Projections
Given the mature and competitive nature of the generic metronidazole market, significant price increases for NDC 51759-0410 are unlikely in the short to medium term.
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with marginal fluctuations driven by inventory management and competitive pricing strategies among generic suppliers. A potential for slight decreases may occur if new competitors enter or if there are aggressive rebate programs offered by major suppliers.
- Medium-Term (3-5 years): The market is likely to continue its trajectory of generic competition. Without significant shifts in demand or new therapeutic alternatives emerging that broadly displace metronidazole for its core indications, prices will likely continue to experience downward pressure, albeit at a slower pace than during initial generic market entry. Average prices per tablet could trend towards the lower end of the current range ($0.15-$0.25).
- Long-Term (5+ years): Pricing will remain highly dependent on the ongoing prevalence of indicated infections, the development of new, more cost-effective treatments, and the evolution of antimicrobial resistance patterns. However, metronidazole's established efficacy and low cost are likely to sustain its use and maintain competitive pricing for the foreseeable future.
Table 2: Projected Price Trends for NDC 51759-0410
| Time Horizon | Projected Price Trend | Rationale |
|---|---|---|
| Short-Term | Stable to Slightly Decreasing | Continued generic competition, ongoing PBM negotiations, and inventory management. Price declines are likely to be modest, driven by competitive pressure and rebate strategies rather than fundamental cost reductions or shifts in supply. |
| Medium-Term | Gradual Decrease | Maturation of the generic market with established players vying for market share. Pricing power will remain with payers. Potential for consolidation among manufacturers or shifts in API sourcing could introduce minor price volatility, but the overall trend will be downward. |
| Long-Term | Stable with Potential for Minor Volatility | Pricing will be influenced by disease prevalence, emergence of alternative therapies, and antibiotic resistance trends. Metronidazole's established position in treating specific anaerobic infections, coupled with its low cost, suggests continued demand. Significant price increases are unlikely without a major disruption in supply or a dramatic shift in treatment paradigms. Minor fluctuations may arise from API cost changes or supply chain events. |
Key Takeaways
- NDC 51759-0410 is Metronidazole 500 mg Oral Tablets manufactured by Breckenridge Pharmaceutical, Inc.
- The market for this product is characterized by mature generic competition, leading to competitive pricing.
- Current wholesale prices are estimated to be between $0.15 and $0.30 per tablet.
- Future pricing is projected to remain stable to slightly decreasing in the short term, with a gradual decline expected over the medium term.
- Long-term pricing will be influenced by disease prevalence, therapeutic alternatives, and antibiotic resistance patterns.
Frequently Asked Questions
-
What are the primary indications for Metronidazole 500 mg tablets? Metronidazole 500 mg tablets are primarily used to treat infections caused by anaerobic bacteria and certain protozoa, including bacterial vaginosis, trichomoniasis, amebiasis, and Clostridium difficile-associated diarrhea.
-
Who are the main competitors for Breckenridge Pharmaceutical's Metronidazole 500 mg tablets? Major generic competitors in the metronidazole tablet market include Teva Pharmaceuticals, Viatris (formerly Mylan), and Aurobindo Pharma, among others.
-
What factors are most likely to cause a significant price increase for NDC 51759-0410? A significant price increase would likely stem from a major supply chain disruption affecting API availability, a substantial reduction in the number of competing generic manufacturers, or a sudden surge in demand not met by existing supply capacity.
-
How do PBM negotiations impact the net price of Metronidazole 500 mg tablets? PBM negotiations result in significant rebates and discounts negotiated with manufacturers. This means the net price paid by pharmacies and payers is considerably lower than the published Wholesale Acquisition Cost (WAC).
-
Are there any patent exclusivities that might affect the pricing or availability of NDC 51759-0410? As a generic product, metronidazole has long been off-patent. NDC 51759-0410 benefits from the generic market established under the Hatch-Waxman Act, meaning there are no active substance patents that would grant exclusivity to a single manufacturer for this formulation.
Citations
[1] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/
[2] National Institutes of Health. (n.d.). Metronidazole. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a681010.html
[3] United States Pharmacopeia. (n.d.). Metronidazole. USP-NF.
[4] Infectious Diseases Society of America. (2017). Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children. https://www.idsociety.org/practice-guideline/clostridioides-difficile-infection
[5] IQVIA. (2023). Global Generics Market Report. (Proprietary Market Data).
[6] U.S. Food and Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs
[7] U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act and Generic Drugs. Retrieved from https://www.fda.gov/drugs/patent-litigation/hatch-waxman-act-and-generic-drugs
More… ↓
